Lenalidomide in solid tumors Angela SeglerApostolia-Maria Tsimberidou Review Article 15 May 2012 Pages: 1393 - 1406
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib Francesco GrossiErika RijavecPaolo Pronzato Original Article 21 February 2012 Pages: 1407 - 1412
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas Mei DongZhi-Qiang NingFeng-Yi Feng Original Article 24 February 2012 Pages: 1413 - 1422
Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent Elizabeth RayburnWei WangRuiwen Zhang Original Article 25 February 2012 Pages: 1423 - 1431
A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults Joseph P. BoniCathie LeisterDaryl Sonnichsen Original Article 26 February 2012 Pages: 1433 - 1442
The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum Fa-Jun XiePeng ZhaoYi-Ping Zhang Original Article 28 February 2012 Pages: 1443 - 1448
Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity Omar N. Al SafarjalaniReem RaisMahmoud H. el Kouni Original Article 29 February 2012 Pages: 1449 - 1455
Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study Robert S. JansenHilde RosingJos H. Beijnen Original Article 01 March 2012 Pages: 1457 - 1466
Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors E. CalvoJ. B. VermorkenJ. Bennouna Original Article 01 March 2012 Pages: 1467 - 1475
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors Hajime AsahinaYosuke TamuraTomohide Tamura Original Article Open access 02 March 2012 Pages: 1477 - 1486
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules Qian LiuJessica D. SunCharles P. Hart Original Article 02 March 2012 Pages: 1487 - 1498
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer Manabu EmiJun HiharaYuji Murakami Original Article 02 March 2012 Pages: 1499 - 1505
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients David A. ReardonCharles A. ConradW. K. Alfred Yung Original Article 07 March 2012 Pages: 1507 - 1518
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma Aaron M. TeitelbaumJose L. GallardoDavid M. Ferguson Original Article 09 March 2012 Pages: 1519 - 1527
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer Maiko AsakumaMichiko YamamotoNoriyuki Masuda Original Article 14 March 2012 Pages: 1529 - 1536
Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients Manabu KumeHiroyuki YasuiTsutomu Nakamura Original Article 22 March 2012 Pages: 1537 - 1544
The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells Yuko TakebaNaoki MatsumotoTakehito Otsubo Original Article 06 April 2012 Pages: 1545 - 1555
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin Federica GrossoMaurizio D’IncalciIan Judson Original Article Open access 07 April 2012 Pages: 1557 - 1565
Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions Binfeng XiaTycho HeimbachEugene Tan Original Article 11 April 2012 Pages: 1567 - 1582
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men M. AcharyaA. BernardN. Tran Original Article Open access 18 April 2012 Pages: 1583 - 1590
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens M. J. LamasG. DuranF. Barros Original Article 26 April 2012 Pages: 1591 - 1599
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines Annett MuellerErika BachmannMarkus Moehler Original Article 29 April 2012 Pages: 1601 - 1615
An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel Toshitaka UchiyamaHitoshi KannoKayoko Saito Original Article 06 May 2012 Pages: 1617 - 1624
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) Naoya HidaHiroaki OkamotoKoshiro Watanabe Original Article Open access 08 May 2012 Pages: 1625 - 1631
RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR Ziwei LiuQianying YuanJinlan Ruan Original Article 08 May 2012 Pages: 1633 - 1640
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study Alberto ZaniboniEnrico AitiniRoberto Labianca Original Article 11 May 2012 Pages: 1641 - 1645
Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies Zhen-Hua WangQin-Yan GaoJing-Yuan Fang Original Article 18 May 2012 Pages: 1647 - 1655
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies Prithviraj BoseEdward B. PerkinsSteven Grant Clinical Trial Report 15 February 2012 Pages: 1657 - 1667
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model Sarah R. MuddMartin J. VoorbachMark Day Short Communication 12 February 2012 Pages: 1669 - 1672
Ascorbic acid and healthy lymphocytes: a way to explain anticancer activity? Sandra RodemeisterDonatus NohrHans K. Biesalski Letter to the Editor 14 February 2012 Pages: 1673 - 1674